Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BRD4 Antibodies:
anti-Mouse (Murine) BRD4 Antibodies:
anti-Rat (Rattus) BRD4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal BRD4 Primary Antibody for ICC, IF - ABIN438710
Rahman, Sowa, Ottinger, Smith, Shi, Harper, Howley: The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. in Molecular and cellular biology 2011
Show all 3 Pubmed References
Human Polyclonal BRD4 Primary Antibody for ChIP, WB - ABIN2668492
Flajollet, Rachez, Ploton, Schulz, Gallais, Métivier, Pawlak, Leray, Issulahi, Héliot, Staels, Salbert, Lefebvre: The elongation complex components BRD4 and MLLT3/AF9 are transcriptional coactivators of nuclear retinoid receptors. in PLoS ONE 2013
Show all 2 Pubmed References
Human Polyclonal BRD4 Primary Antibody for ICC, IF - ABIN4285227
Zuber, Shi, Wang, Rappaport, Herrmann, Sison, Magoon, Qi, Blatt, Wunderlich, Taylor, Johns, Chicas, Mulloy, Kogan, Brown, Valent, Bradner, Lowe, Vakoc: RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. in Nature 2011
Show all 2 Pubmed References
Brd4 associates with mitotic chromosomes throughout early zebrafish embryogenesis
MS645 blocks BRD4 binding to transcription enhancer/mediator proteins MED1 (show MED1 Antibodies) and YY1 (show YY1 Antibodies) with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent BrD inhibition.
Study shows that BRD4 is significantly highly expressed in gastric cancer patients and cell lines and positively regulates the expression of c-MYC (show MYC Antibodies) through transcription regulation and epigenetic levels. Functionally, these result demonstrate that the knockdown of BRD4 represses the proliferation and induces the apoptosis of gastric cancer cells through repression of c-MYC (show MYC Antibodies).
BRD4 hyperphosphorylation is associated with cellular transformation in NUT midline carcinoma
Results suggest structure-based drug design of bromodomain-containing protein 4 (Brd4) inhibitors.
Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3 (show PAX3 Antibodies)-FOXO1 (show FOXO1 Antibodies)-occupied super enhancers. Furthermore, PAX3 (show PAX3 Antibodies)-FOXO1 (show FOXO1 Antibodies) recruits and requires the BET bromodomain protein BRD4 to function at super enhancers, resulting in a complete dependence on BRD4 and a significant susceptibility to BRD inhibition
Our data suggested that downregulation of BRD4 in gallbladder cancer (GBC) cells induced apoptosis by PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) pathway. Inhibition of BRD4 expression may be a novel therapeutic strategy for patients with GBC.
these results highlighted the significant genetic contribution of the ARID1B (show ARID1B Antibodies) variant, rs73013281, to susceptibility for HCC (show FAM126A Antibodies), especially in interaction with physical activity.
In pluripotent cells, Brd2 (show BRD2 Antibodies)-Brd4 occupy Nodal gene regulatory elements (NREs), but only Brd4 is required for pluripotency gene expression. Brd4 downregulation facilitates pluripotent exit and drives enhanced Brd2 (show BRD2 Antibodies) NRE occupancy, thereby unveiling a specific function for Brd2 (show BRD2 Antibodies) in differentiative Nodal-Smad2 (show SMAD2 Antibodies) signalling
Findings reveal that PCa (show FLVCR1 Antibodies)-associated ERG (show ERG Antibodies) can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG (show ERG Antibodies)-mediated cell invasion and PCa (show FLVCR1 Antibodies) progression.
Our data strongly support the use of CCR2 (show CCR2 Antibodies) and CD180 (show CD180 Antibodies) mRNAs as whole blood pharmacodynamic (PD)biomarkers for BRD4 inhibitors, especially in situations where paired tumor biopsies are unavailable. In addition, they can be used as tumor-based PD biomarkers for hematologic tumors.
results suggest that rhythmic expression of Sglt1 (show SLC5A1 Antibodies) is regulated at the mRNA transcriptional elongation level by enhancing the binding of the BRD4-P-TEFb (show CCNT1 Antibodies) complex to acetylated histones at the gene upon BMAL1 (show ARNTL Antibodies)-CLOCK binding to Sglt1 (show SLC5A1 Antibodies)
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
By modulating the translation of IkappaBalpha (show NFKBIA Antibodies) via the Mnk2 (show MKNK2 Antibodies)-eIF4E (show EIF4E Antibodies) pathway, Brd4 provides an additional layer of control for NF-kappaB (show NFKB1 Antibodies)-dependent inflammatory gene expression and inflammatory response.
Using compound selectivity engineering and CRISPR/Cas9 genome editing, distinct functions for Erk5 (show MAPK7 Antibodies) and Brd4 in pluripotency regulation of mouse embryonic stem cells have been revealed.
Long-term treatment with bromodomain-containing protein 4 (BRD4) inhibitors caused telomere shortening in both mouse and human cells, suggesting BRD4 plays a role in telomere maintenance in vivo.
Fmr1 (show FMR1 Antibodies) knockout (KO) mice show widespread changes in histone marks as well as transcriptional misregulation resulting in increased expression of many critical synaptic genes. Data suggest that one chromatin target of FMRP (show FMR1 Antibodies), the reader protein Brd4, appears to be significantly involved in this transcriptional disruption.
The functional domains of mouse BRD4 and its role in transcription are described. Review.
Brd2 (show BRD2 Antibodies) and Brd4 genetic transcription required for Th17 cell development and adaptive immunity.
These data provide a detailed mechanism for how activated NF-kappaB (show NFKB1 Antibodies) and BRD4 control epithelial-mesenchymal transition initiation and transcriptional elongation in model airway epithelial cells in vitro and in a murine pulmonary fibrosis model in vivo.
DOT1L (show DOT1L Antibodies), via dimethylated histone H3 (show HIST3H3 Antibodies) K79, facilitates histone H4 (show HIST1H4H Antibodies) acetylation, which in turn regulates the binding of BRD4 to chromatin in acute lymphoblastic leukemia.
The protein encoded by this gene is homologous to the murine protein MCAP, which associates with chromosomes during mitosis, and to the human RING3 protein, a serine/threonine kinase. Each of these proteins contains two bromodomains, a conserved sequence motif which may be involved in chromatin targeting. This gene has been implicated as the chromosome 19 target of translocation t(15\;19)(q13\;p13.1), which defines an upper respiratory tract carcinoma in young people. Two alternatively spliced transcript variants have been described.
Bromodomain-containing protein 4B
, bromodomain-containing protein 4B
, bromodomain containing 4
, bromodomain-containing protein 4
, bromodomain 4
, bromodomain-containing protein 4-like
, bromodomain containing protein 4
, bromodomain-containing 4
, chromosome-associated protein
, bromodomain-containing 5
, fsh-like protein
, mitotic chromosome-associated protein